About Esmolol Dosing

This guide provides clinical context for the Esmolol Infusion Calculator. Esmolol is a short-acting, cardioselective beta-1 blocker used for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter, and for the short-term treatment of tachycardia and hypertension. Its rapid onset and short half-life make it ideal for situations requiring precise, titratable heart rate control.

Outputs Explained

The calculator provides three primary outputs based on your inputs:

• Total Loading Dose (mg): This is the initial, weight-based dose given to rapidly achieve a therapeutic concentration. The calculator uses a standard dose of 500 mcg/kg.
• Loading Volume (mL): This is the volume of the selected esmolol concentration required to deliver the total loading dose. It is typically administered over one minute.
• Maintenance Infusion Rate (mL/hr): This is the continuous infusion rate required to maintain the desired therapeutic effect after the loading dose. This value is the primary focus for ongoing titration.

How to Use the Calculator

1. Enter Patient Weight: Input the patient's weight and select the correct unit (kg or lbs). The tool automatically converts lbs to kg for calculations.
2. Select Drug Concentration: Choose from standard premixed concentrations (10 mg/mL or 20 mg/mL) or select "Custom" to input the total drug amount (mg) and total solution volume (mL) for non-standard preparations.
3. Set Maintenance Dose: Enter the desired maintenance infusion dose in mcg/kg/min. The calculator defaults to a starting dose of 50 mcg/kg/min.
4. Review Results: The calculator will instantly display the loading dose volume and the maintenance infusion rate. A titration table can also be generated to guide dose adjustments.

Dosing Overview

Standard esmolol administration follows a two-step process of a loading dose followed by a continuous maintenance infusion.

• Loading Dose: A fixed dose of 500 mcg/kg is administered over 1 minute to quickly establish a therapeutic level. This may be repeated if necessary.
• Maintenance Infusion: The infusion begins immediately after the loading dose, typically at 50 mcg/kg/min.
• Titration: The maintenance dose can be titrated every 4 minutes by increments of 50 mcg/kg/min to achieve the desired heart rate. Most patients respond to doses between 50 and 200 mcg/kg/min. Doses up to 300 mcg/kg/min may be used but are associated with an increased risk of adverse effects, particularly hypotension.

Switching to Oral Agents

Due to its very short half-life (~9 minutes), a careful transition protocol is required when switching from intravenous esmolol to an oral agent (e.g., metoprolol, diltiazem). After the patient is stable and the desired heart rate is achieved, the oral agent can be initiated. The esmolol infusion rate should be reduced by 50% approximately 30 minutes after the first dose of the oral medication. If the patient's condition remains stable after one hour, the esmolol infusion can be discontinued.

Infusion Interruption (Missed Dose)

As a continuous infusion, there is no concept of a "missed dose." However, any interruption in the infusion (e.g., IV line failure) will result in a rapid loss of therapeutic effect. If an interruption occurs, the infusion should be restarted as soon as possible at the previously effective rate. A re-bolus (loading dose) may be considered depending on the duration of the interruption and the patient's clinical status.

Safety Alerts

• Hypotension: The most common adverse effect. Monitor blood pressure closely during administration, especially during loading and titration.
• Bradycardia: Can occur, particularly in patients with underlying sinus node dysfunction.
• Contraindications: Esmolol is contraindicated in patients with severe sinus bradycardia, heart block greater than first degree, cardiogenic shock, or overt heart failure.
• Extravasation: Esmolol can cause irritation and necrosis if extravasation occurs. Monitor the IV site closely.

Frequently Asked Questions

References

1. U.S. Food and Drug Administration. (2018). BREVIBLOC (esmolol hydrochloride) prescribing information. Retrieved from FDA.gov
2. Weant, K. A., & Townsend, K. B. (2007). Esmolol. In Critical Care Clinics, 23(4), 759-775.
3. Miner, J. R., & Olson, D. W. (2018). Esmolol. In StatPearls [Internet]. StatPearls Publishing. Retrieved from NCBI StatPearls
4. January, C. T., Wann, L. S., Alpert, J. S., et al. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Journal of the American College of Cardiology, 64(21), e1-e76.